Kyoto University: Development of nasal vaccine for dementia: iPS Cell Research Institute
-Immunotherapy and molecular imaging by gene therapy-
IPS Cell Research Institute: Professor Inoue,
In collaboration with the National Institute of Quantum Science and Technology, iPS Cell Research Institute has produced a nasal vaccine against tau protein using gene therapy / Sendai virus vectors.
Tau protein is a key molecule in dementia that exhibits tauopathy.
A nasal vaccine was prepared using a gene therapy / Sendai virus vector.
Therapeutic effect of tauopathy model mice was measured using molecular imaging technology
Experimental results: Improvement of cognitive function
As a result, with the nasal vaccine against tau protein, tauopathy model mice
Increased anti-tau antibody titers in the brain,
Reduced tau protein accumulation,
Improvement of glial inflammation,
Improvement of brain atrophy,
Showed improved cognitive function.
This study will contribute to the development of vaccines to control dementia such as Alzheimer’s disease.
The results of this research were published in the online version of the international academic journal “NPJ Vaccines” on March 25, 2020.
Kyoto University
http://www.kyoto-u.ac.jp/ja/research/research_results/2019/200325_1.html
Nasal vaccine for dementia, prevention of tau protein accumulation @ Kyoto University and RIKEN | Nikkan Kogyo Shimbun Electronic version